title: Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
abstract: Risperidone is the most widely used augmenting agent in the treatment of obsessive-compulsive disorder (OCD). However, a recent controlled study found risperidone to be no different from placebo, raising doubts about its effectiveness. In this context, we sought to examine the real-world effectiveness of risperidone from the large database of an OCD clinic in India. A total of 1314 consecutive patients who registered at the OCD clinic between 2004 and 2014 were evaluated with structured interviews and scales. Patients with OCD initiated on risperidone augmentation without concurrent cognitive behavior therapy and who were on stable and adequate doses of serotonin reuptake inhibitors for at least 12 preceding weeks were included for analysis. The primary outcome measure was all-cause discontinuation. Logistic regression was performed to identify the factors predicting improvement with risperidone augmentation. A total of 92 patients were eligible for analysis. Risperidone continued to be used in 23 patients (25%) at the time of last follow-up, and the remaining discontinued either because of ineffectiveness or intolerability. The fall in the Yale-Brown Obsessive-Compulsive Scale scores was significantly greater in patients who continued to take risperidone when compared with those who did not (41.6% vs 3.7%, t = 6.95, P < 0.001). A total of 22 patients (24%) were noted to have at least a 25% reduction on the Yale-Brown Obsessive-Compulsive Scale scores. On regression analysis, no predictors of improvement with risperidone augmentation could be identified. The study demonstrated, in a real-world setting, that risperidone may be a useful augmenting agent in a proportion of patients with partial/poor response to serotonin reuptake inhibitors.
authors.affiliation: From the OCD Clinic, Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
authors.forename: Aditya
authors.initials: A
authors.lastname: Hegde
authors.forename: Bangalore G
authors.initials: BG
authors.lastname: Kalyani
authors.forename: Shyam Sundar
authors.initials: SS
authors.lastname: Arumugham
authors.forename: Janardhanan C
authors.initials: JC
authors.lastname: Narayanaswamy
authors.forename: Suresh Bada
authors.initials: SB
authors.lastname: Math
authors.forename: Y C Janardhan
authors.initials: YC
authors.lastname: Reddy
mesh_terms: D000328:Adult; D000359:Aftercare; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015897:Comorbidity; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007194:India; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000453:epidemiology; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000453:epidemiology; D017063:Outcome Assessment, Health Care; D018967:Risperidone / Q000008:administration & dosage / Q000494:pharmacology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone; D017367:Selective Serotonin Reuptake Inhibitors